Health

BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights 

WASHINGTON — Everyone wants to know whether Michelle McMurry-Heath, the newly minted president of the Biotechnology Innovation Organization, will be President Biden’s pick to lead the Food and Drug Administration. And whether, quite frankly, she wants the job.

So STAT asked her just that — and asked, too, about the FDA’s controversial decision to approve Aduhelm for Alzheimer’s, and whether the drug industry should have gotten behind a high-profile, bipartisan drug pricing package it has opposed vehemently.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED



Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button